WS #15598
Natera received FDA Breakthrough Device Designation for its multi-cancer early detection (MCED) assay, a significant catalyst for the biotech sector. Humana shares rallied on positive Medicare Star Ratings, while NovaGold was highlighted as a permitted gold giant priced for the worst. These developments indicate strong performance in healthcare and healthcare services, driven by regulatory approvals and favorable government program ratings.
Healthcare and Biotech Developments
Natera received FDA Breakthrough Device Designation for its multi-cancer early detection (MCED) assay, a significant catalyst for the biotech sector. Humana shares rallied on positive Medicare Star Ratings, while NovaGold was highlighted as a permitted gold giant priced for the worst. These developments indicate strong performance in healthcare and healthcare services, driven by regulatory approvals and favorable government program ratings.